Radiofrequency ablation combined with transarterial chemoembolization for intermediate hepatocellular carcinoma
- 25 February 2013
- journal article
- research article
- Published by Wiley in Hepatology Research
- Vol. 44 (2), 194-200
- https://doi.org/10.1111/hepr.12100
Abstract
Aim Radiofrequency ablation therapy (RFA) combined with transarterial chemoembolization (TACE) (combination therapy) is effective for early‐stage hepatocellular carcinoma (HCC). The aim of this study was to compare the long‐term effects of combination therapy with supportive care alone for intermediate HCC. Methods The study included 58 patients with intermediate HCC who received combination therapy (n = 34) or supportive care alone (n = 24). The inclusion criteria were a single nodule of more than 50 mm in diameter or two to three nodules, each measuring more than 30 mm in diameter, or more than three nodules, no vascular invasion and no extrahepatic metastasis. Results The overall survival rates at 1, 2, 3 and 5 years of the combination therapy group (91%, 65%, 53% and 27%, respectively) were significantly better (P < 0.0001) than those of the supportive care group (42%, 8%, 8% and 0%, respectively). Multivariate analysis identified treatment modality (combination therapy vs supportive care alone: P < 0.0001, risk ratio [RR] = 4.290 [95% confidence interval [CI] = 2.157–8.529]) and serum α‐fetoprotein (P = 0.017, RR = 2.318 [95% CI = 1.166–4.610]) as independent and significant factors of overall survival. Conclusion The combination of TACE and RFA is a safe and effective therapy in patients with intermediate HCC.Keywords
This publication has 28 references indexed in Scilit:
- Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinomaCancer, 2010
- Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysisLiver International, 2010
- Liver Resection or Combined Chemoembolization and Radiofrequency Ablation Improve Survival in Patients with Hepatocellular CarcinomaDigestion, 2007
- Surveillance Program for Early Detection of Hepatocellular Carcinoma in JapanJournal of Clinical Gastroenterology, 2006
- Percutaneous ethanol injection for small hepatocellular carcinoma: Therapeutic efficacy based on 20-year observationJournal of Hepatology, 2005
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatology, 2003
- Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosisCancer, 2002
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaHepatology, 2002
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL ConferenceJournal of Hepatology, 2001